ONGOING CLINICAL TRIAL: A PROSPECTIVE MULTICENTRE, PHASE 2B RANDOMISED, CONTROLLED DOUBLE-BLIND TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF PERISPINAL ETANERCEPT ON QUALITY OF LIFE

被引：0
|
作者：
Thijs, V. [1 ]
Bernhardt, J. [1 ]
Cloud, G. [2 ]
Churilov, L. [3 ]
Sprigg, N. [4 ]
Parsons, B. [1 ]
Gilchrist, N. [5 ,6 ]
Walker, M. [6 ,7 ]
Bath, P. [7 ]
机构：
[1] Florey Inst Neurosci & Mental Hlth, Stroke Theme, Heidelberg, Vic, Australia
[2] Alfred Hlth, Stroke, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne Med Sch, Melbourne, Vic, Australia
[4] Univ Nottingham, Sch Med, Stroke Trials Unit, Nottingham, England
[5] CGM Res Trust, Cgm, Christchurch, New Zealand
[6] Univ Nottingham UK, Div Rehabil Ageing & Wellbeing, Nottingham, England
[7] Nottingham Univ Hosp NHS Trust, Stroke, Dept Med, Nottingham, England
来源：
INTERNATIONAL JOURNAL OF STROKE | 2021年 / 16卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
WSC21-222
引用
收藏
页码：27 / 27
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial
    Laurencin, Chloe
    Timestit, Noemie
    Marques, Ana
    Duchez, Domitille Dilly
    Giordana, Caroline
    Meoni, Sara
    Huddlestone, Marine
    Danaila, Teodor
    Anheim, Mathieu
    Klinger, Helene
    Vidal, Tiphaine
    Fatisson, Marion
    Caire, Catherine
    Nourredine, Mikail
    Boulinguez, Philippe
    Dhelens, Carole
    Ballanger, Benedicte
    Prange, Stephane
    Bin, Sylvie
    Thobois, Stephane
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 4851 - 4859
  • [22] Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial
    Chloé Laurencin
    Noémie Timestit
    Ana Marques
    Domitille Dilly Duchez
    Caroline Giordana
    Sara Meoni
    Marine Huddlestone
    Teodor Danaila
    Mathieu Anheim
    Hélène Klinger
    Tiphaine Vidal
    Marion Fatisson
    Catherine Caire
    Mikail Nourredine
    Philippe Boulinguez
    Carole Dhelens
    Bénédicte Ballanger
    Stéphane Prange
    Sylvie Bin
    Stéphane Thobois
    Journal of Neurology, 2023, 270 : 4851 - 4859
  • [23] Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation
    Ralph, Stephen J.
    Weissenberger, Andrew
    Bonev, Ventzislav
    King, Liam D.
    Bonham, Mikaela D.
    Ferguson, Samantha
    Smith, Ashley D.
    Goodman-Jones, Adrienne A.
    Espinet, Anthony J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (03) : 311 - 326
  • [24] Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial
    Kloppenburg, Margreet
    Ramonda, Roberta
    Bobacz, Klaus
    Kwok, Wing-Yee
    Elewaut, Dirk
    Huizinga, Tom W. J.
    Kroon, Feline P. B.
    Punzi, Leonardo
    Smolen, Josef S.
    Cruyssen, Bert Vander
    Wolterbeek, Ron
    Verbruggen, Gust
    Wittoek, Ruth
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (12) : 1757 - 1764
  • [25] The Efficacy and Safety of Xinjia Xuanbai Chengqi Granules in Acute Exacerbation of COPD: A Multicentre, Randomised, Double-Blind, Controlled Trial
    Qi, Ruihan
    Zhang, Hongchun
    Li, Demin
    Gao, Feng
    Miao, Qing
    Chen, Sheng
    Huang, Yan
    Wu, Lei
    Lu, Zhenhui
    Hu, Haibo
    Li, Erran
    Chen, Zhibin
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [26] Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
    Goadsby, Peter J.
    Dodick, David W.
    Ailani, Jessica
    Trugman, Joel M.
    Finnegan, Michelle
    Lu, Kaifeng
    Szegedi, Armin
    LANCET NEUROLOGY, 2020, 19 (09): : 727 - 737
  • [27] The Efficacy and Safety of Xinjia Xuanbai Chengqi Granules in Acute Exacerbation of COPD: A Multicentre, Randomised, Double-Blind, Controlled Trial
    Qi, Ruihan
    Zhang, Hongchun
    Li, Demin
    Gao, Feng
    Miao, Qing
    Chen, Sheng
    Huang, Yan
    Wu, Lei
    Lu, Zhenhui
    Hu, Haibo
    Li, Erran
    Chen, Zhibin
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [28] Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial
    Beraha, Esther M.
    Salemink, Elske
    Goudriaan, Anna E.
    Bakker, Abraham
    de Jong, David
    Smits, Natasha
    Zwart, Jan Willem
    van Geest, Dick
    Bodewits, Pieter
    Schiphof, Tom
    Defourny, Harma
    van Tricht, Mirjam
    van den Brink, Wim
    Wiers, Reinout W.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (12) : 1950 - 1959
  • [29] Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
    Cid, Maria C.
    Unizony, Sebastian H.
    Blockmans, Daniel
    Brouwer, Elisabeth
    Dagna, Lorenzo
    Dasgupta, Bhaskar
    Hellmich, Bernhard
    Molloy, Eamonn
    Salvarani, Carlo
    Trapnell, Bruce C.
    Warrington, Kenneth J.
    Wicks, Ian
    Samant, Manoj
    Zhou, Teresa
    Pupim, Lara
    Paolini, John F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 653 - 661
  • [30] Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial
    Ji, Linong
    Tong, Xiaolin
    Wang, Hongyuan
    Tian, Haoming
    Zhou, Huimin
    Zhang, Lili
    Li, Qifu
    Wang, Yizhong
    Li, Hongmei
    Liu, Min
    Yang, Hongjie
    Gao, Yanbin
    Li, Yan
    Li, Quanmin
    Guo, Xiaohui
    Yang, Gangyi
    Zhang, Zhongai
    Zhou, Zhiguang
    Ning, Guang
    Chen, Yingli
    Paul, Sanjoy
    PLOS ONE, 2013, 8 (02):
12345